カテゴリ： GlobalData, アメリカ, 企業調査

Merck & Co Inc (MRK)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Merck & Co Inc (MRK) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011104
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月21日
◆ページ数：141
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Merck & Co Inc (Merck) focuses on the discovery, development, manufacture and commercialization of prescription pharmaceuticals, biologic therapies, vaccines and animal healthcare products. It offers prescription products for treating cardiovascular, cancer, immunology, infectious, respiratory and women’s diseases, diabetes and vaccines. The company provides animal health products including vaccines, poultry products, livestock products and aquaculture products. Merck sells pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company’s operations outside the US are conducted primarily through subsidiaries. It offers its products in US, Europe, Middle East and Africa, Asia Pacific, Japan, Latin America and other countries. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Merck & Co Inc (MRK) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Merck & Co Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Merck & Co Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Merck & Co Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Merck & Co Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
Merck & Co Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Merck & Co Inc, Medical Equipment, Deal Details 18
Venture Financing 18
Grail Raises USD914 Million in First Tranche of Series B Financing 18
Livongo Health Raises USD44.5 Million in Series C Financing Round 21
WellDoc Raises USD22 Million in First Tranche of Series B Financing 23
CareSync Raises USD18 Million in Series B Financing 24
Navigating Cancer Raises USD10 Million in Financing Round 25
RaNA Therapeutics Raises USD55 Million in series B Financing 26
MedCPU Raises USD8 Million in Financing Round 27
ClearData Networks Raises USD25 Million in Series C Financing 28
Liaison Technologies Raises Funds through Venture Financing 29
Daktari Diagnostics Raises USD15.5 Million in Series D Financing 30
Aventura Raises USD14 Million in Series C Financing 31
WiserTogether Raises USD9 Million in Series B Venture Financing 32
Healthsense Raises USD10 Million in Venture Financing 33
ElectroCore Raises Additional USD10 Million in Second Tranche of Venture Financing 34
MedCPU Raises USD9.3 Million in Series B Financing 35
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 36
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 37
WellDoc Raises US$15.7 Million In Venture Financing 38
ClearData Networks Raises US$14 Million In Series B Financing 39
GenomeDx Biosciences Raises Funds Through Series B Financing 40
PatientSafe Solutions Raises US$27 Million In Series C Venture Financing 41
Aviir Raises US$20 Million In Venture Financing 43
eHealth Technologies Raises US$6 Million In Series D Financing 45
Remedy Informatics Raises US$6 Million In Venture Financing 46
Healthsense Raises US$7 Million In Series D Financing 47
Liaison Technologies Raises US$30 Million In Venture Financing 48
Physicians Interactive Holdings Secures US$8.5 Million In Venture Financing 49
Aviir Secures US$10 Million In Venture Financing 50
Daktari Diagnostics Secures US$5 Million In Venture Financing 51
HTG Molecular USD0.5 Million in Second Tranche of Series D Financing 52
High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 53
HTG Molecular Raises USD15.7 Million in First Tranche of Series D Financing 54
Private Equity 55
Merck Global Health Acquires Physicians Interactive From Perseus 55
Partnerships 56
Cerveau Technologies Enters into Licensing Agreement with Merck 56
Merck Enters Into Licensing Agreement With Luminex To Develop Companion Diagnostic Device 57
Merck Enters Into Licensing Agreement With Vaxxas For Nanopatch Technology 58
HTG Molecular Diagnostics Enters Into Licensing Agreement With Merck For Breast Cancer Marker Patent Portfolio 59
CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 60
OpGen Enters into Research Agreement with Merck 61
Takeda Pharma Enters into Agreement with Koneksa Health 62
Merck Enters into Co-Development Agreement with Amoy Diagnostics 63
Enigma Biomedical Enters into Research Agreement with Biogen and Merck 64
Merck to Enter into Co-Development Agreement with Biocartis 65
Daktari Diagnostics Enters into Agreement with Merck 66
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 67
Dako Enters into Agreement with Merck for Companion Diagnostic Test 68
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 69
Physicians Interactive Enters Into Agreement With Greenway For eCoupon 70
Merck Enters Into Co-Development Agreement With Geisinger Health System 71
Ezose Sciences Enters Into Co-Development Agreement With Merck 72
F. Hoffmann-La Roche Enters Into Co-Development Agreement With Merck 73
Merck Enters Into Licensing Agreement With GE Healthcare For Flutemetamol 74
Equity Offering 75
OpGen Raises USD10.4 Million in Private Placement of Shares and Warrants 75
VirtualScopics Completes First Tranche Of Private Placement Of Shares For US$3 Million 77
Debt Offering 78
Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 78
Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 79
Acquisition 80
OpGen Acquires AdvanDx 80
Physicians Interactive Acquires Tomorrow Networks 81
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 82
Physicians Interactive Acquires InfoMedics, Provider Of Patient Feedback Solutions 84
Merck & Co Inc – Key Competitors 85
Merck & Co Inc – Key Employees 86
Merck & Co Inc – Locations And Subsidiaries 88
Head Office 88
Other Locations & Subsidiaries 88
Joint Venture 111
Recent Developments 112
Strategy And Business Planning 112
Jul 17, 2017: Governor Abbott Announces Merck IT Hub In Austin 112
Financial Announcements 113
Oct 27, 2017: Merck Announces Third-Quarter 2017 Financial Results 113
Jul 28, 2017: Merck Announces Second-Quarter 2017 Financial Results 116
May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 119
Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 121
Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results 123
May 05, 2016: Merck Announces First-Quarter 2016 Financial Results 126
Feb 03, 2016: Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results 128
Corporate Communications 131
Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 131
Apr 06, 2017: Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency 132
Mar 07, 2016: Merck Names Sanat Chattopadhyay President of Merck Manufacturing Division; Will Succeed Willie A. Deese Who Will Retire 133
Legal and Regulatory 134
Jan 15, 2016: Merck Sues Merck for Improper Use of “Merck” 134
Government and Public Interest 135
Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 135
Product News 136
Sep 27, 2016: IDH and CIC Mutations Provide Prognostic Information for Grade II and III Gliomas 136
May 05, 2016: Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer released 137
Apr 14, 2016: Quest Launches New Hepatitis C Virus Test Capabilities for Recently FDA-approved Antiviral Therapies 138
Other Significant Developments 139
Jan 25, 2017: Daktari Achieves Milestone in Its Merck HCV Collaboration 139
Jun 08, 2016: Merck Expands its Investment Fund Merck Ventures 140
Appendix 141
Methodology 141
About GlobalData 141
Contact Us 141
Disclaimer 141

List of Tables
Merck & Co Inc, Medical Equipment, Key Facts, 2016 2
Merck & Co Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Merck & Co Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Merck & Co Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Merck & Co Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Merck & Co Inc, Deals By Market, 2011 to YTD 2017 11
Merck & Co Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Grail Raises USD914 Million in First Tranche of Series B Financing 18
Livongo Health Raises USD44.5 Million in Series C Financing Round 21
WellDoc Raises USD22 Million in First Tranche of Series B Financing 23
CareSync Raises USD18 Million in Series B Financing 24
Navigating Cancer Raises USD10 Million in Financing Round 25
RaNA Therapeutics Raises USD55 Million in series B Financing 26
MedCPU Raises USD8 Million in Financing Round 27
ClearData Networks Raises USD25 Million in Series C Financing 28
Liaison Technologies Raises Funds through Venture Financing 29
Daktari Diagnostics Raises USD15.5 Million in Series D Financing 30
Aventura Raises USD14 Million in Series C Financing 31
WiserTogether Raises USD9 Million in Series B Venture Financing 32
Healthsense Raises USD10 Million in Venture Financing 33
ElectroCore Raises Additional USD10 Million in Second Tranche of Venture Financing 34
MedCPU Raises USD9.3 Million in Series B Financing 35
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 36
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 37
WellDoc Raises US$15.7 Million In Venture Financing 38
ClearData Networks Raises US$14 Million In Series B Financing 39
GenomeDx Biosciences Raises Funds Through Series B Financing 40
PatientSafe Solutions Raises US$27 Million In Series C Venture Financing 41
Aviir Raises US$20 Million In Venture Financing 43
eHealth Technologies Raises US$6 Million In Series D Financing 45
Remedy Informatics Raises US$6 Million In Venture Financing 46
Healthsense Raises US$7 Million In Series D Financing 47
Liaison Technologies Raises US$30 Million In Venture Financing 48
Physicians Interactive Holdings Secures US$8.5 Million In Venture Financing 49
Aviir Secures US$10 Million In Venture Financing 50
Daktari Diagnostics Secures US$5 Million In Venture Financing 51
HTG Molecular USD0.5 Million in Second Tranche of Series D Financing 52
High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 53
HTG Molecular Raises USD15.7 Million in First Tranche of Series D Financing 54
Merck Global Health Acquires Physicians Interactive From Perseus 55
Cerveau Technologies Enters into Licensing Agreement with Merck 56
Merck Enters Into Licensing Agreement With Luminex To Develop Companion Diagnostic Device 57
Merck Enters Into Licensing Agreement With Vaxxas For Nanopatch Technology 58
HTG Molecular Diagnostics Enters Into Licensing Agreement With Merck For Breast Cancer Marker Patent Portfolio 59
CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 60
OpGen Enters into Research Agreement with Merck 61
Takeda Pharma Enters into Agreement with Koneksa Health 62
Merck Enters into Co-Development Agreement with Amoy Diagnostics 63
Enigma Biomedical Enters into Research Agreement with Biogen and Merck 64
Merck to Enter into Co-Development Agreement with Biocartis 65
Daktari Diagnostics Enters into Agreement with Merck 66
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 67
Dako Enters into Agreement with Merck for Companion Diagnostic Test 68
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 69
Physicians Interactive Enters Into Agreement With Greenway For eCoupon 70
Merck Enters Into Co-Development Agreement With Geisinger Health System 71
Ezose Sciences Enters Into Co-Development Agreement With Merck 72
F. Hoffmann-La Roche Enters Into Co-Development Agreement With Merck 73
Merck Enters Into Licensing Agreement With GE Healthcare For Flutemetamol 74
OpGen Raises USD10.4 Million in Private Placement of Shares and Warrants 75
VirtualScopics Completes First Tranche Of Private Placement Of Shares For US$3 Million 77
Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 78
Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 79
OpGen Acquires AdvanDx 80
Physicians Interactive Acquires Tomorrow Networks 81
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 82
Physicians Interactive Acquires InfoMedics, Provider Of Patient Feedback Solutions 84
Merck & Co Inc, Key Competitors 85
Merck & Co Inc, Key Employees 86
Merck & Co Inc, Subsidiaries 88
Merck & Co Inc, Joint Venture 111

★海外企業調査レポート[Merck & Co Inc (MRK)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Kalvista Pharmaceuticals Inc (KALV)：医療機器：M&Aディール及び事業提携情報
    Summary Kalvista Pharmaceuticals Inc (Kalvista), formerly Carbylan Therapeutics Inc, is a pharmaceutical company that discovers, develops and commercializes small molecule protease inhibitors. The company’s product candidates are inhibitors of plasma kallikrein, which is being developed for heredita …
  • Electrabel SA：企業の戦略的SWOT分析
    Electrabel SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Beacon Industries Inc.：企業の戦略・SWOT・財務分析
    Beacon Industries Inc. - Strategy, SWOT and Corporate Finance Report Summary Beacon Industries Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Baker Hughes, a GE Co LLC：企業の戦略的SWOT分析
    Baker Hughes, a GE Co LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Biogen, Inc.：企業の戦略・SWOT・財務情報
    Biogen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Biogen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Cencosud SA：戦略・SWOT・企業財務分析
    Cencosud SA - Strategy, SWOT and Corporate Finance Report Summary Cencosud SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Immunocore Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Immunocore Ltd (Immunocore) is a biotechnology company that focuses on the development of immunotherapeutic drugs for the treatment of cancer, infectious diseases and autoimmune diseases. The company develops its drugs using its proprietary T cell receptor (TCR) technology. Its products unde …
  • Pets at Home Limited (PETS)：企業の財務・戦略的SWOT分析
    Pets at Home Limited (PETS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • bluebird bio Inc (BLUE)：製薬・医療：M&Aディール及び事業提携情報
    Summary Bluebird Bio Inc (bluebird bio) is a clinical stage biotechnology company that focuses on the development of new gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as gene therapy, cancer immuno …
  • Great Portland Estates Plc (GPOR)：企業の財務・戦略的SWOT分析
    Great Portland Estates Plc (GPOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Valio Ltd：企業の戦略的SWOT分析
    Valio Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Cabot Corp (CBT)：企業の財務・戦略的SWOT分析
    Cabot Corp (CBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Empresa Nacional del Petroleo：石油・ガス：M&Aディール及び事業提携情報
    Summary Empresa Nacional del Petroleo (ENAP) is a state-owned integrated oil and gas company. It carries out exploration, development and production of hydrocarbons. The company has major upstream operations in Magallanes region of Chile. ENAP also carries out refining, transportation, storage, and …
  • Saudi Basic Industries Corp (2010)：企業の財務・戦略的SWOT分析
    Saudi Basic Industries Corp (2010) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Public Joint-Stock Company Commercial Bank PrivatBank：企業の戦略・SWOT・財務情報
    Public Joint-Stock Company Commercial Bank PrivatBank - Strategy, SWOT and Corporate Finance Report Summary Public Joint-Stock Company Commercial Bank PrivatBank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • OSE Immunotherapeutics (OSE)：企業の財務・戦略的SWOT分析
    Summary OSE Immunotherapeutics (OSE), formerly OSE Pharma SA, is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon and …
  • Tishman Realty & Construction Co., Inc.：企業の戦略・SWOT・財務情報
    Tishman Realty & Construction Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Tishman Realty & Construction Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Voith GmbH & Co KGaA：企業の戦略的SWOT分析
    Voith GmbH & Co KGaA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Meyer Burger Technology AG (MBTN)：企業の財務・戦略的SWOT分析
    Meyer Burger Technology AG (MBTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Team Energy Corp：企業の戦略的SWOT分析
    Team Energy Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆